Open an account

ACADIA Pharmaceuticals

ACAD · NASDAQ

$20.44+$0.64 (+3.23%)TodayMarket closed ·
Prev close $19.80

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Employees
797
Headquarters
San Diego, California
Listed
May 27, 2004
Sector
Health Care
Industry
Biotechnology
Website
acadia.com

ACAD key statistics

Market cap
3.52B
Price-earnings ratio
8.88
Dividend yield
—
Average volume
2.25M
Volume
1.68M
Open price
$20.04
High today
$20.49
Low today
$19.86
52 Week high
$30.96
52 Week low
$18.39

ACADIA Pharmaceuticals (ACAD) at a glance

ACADIA Pharmaceuticals (ACAD) last traded at $20.44, with a market cap of 3.52B and a price-to-earnings ratio of 8.88.

Today the stock has traded between $19.86 and $20.49. The current price is 2.9% above the day's low and 0.2% below its high.

Volume so far is 1.68M shares, below the average of 2.25M shares a day.

Over the past year ACADIA Pharmaceuticals has ranged from $18.39 to $30.96, and now sits 16% of the way up that range.

ACADIA Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $0.18 per share against an estimate of $0.0586.

The average analyst price target is $32.70, 60.0% above the current price, from 18 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

72%of 18 analyst ratings say Buy
  • Buy72.2%
  • Hold27.8%
  • Sell0.0%
Price target · 21 analystsAvg $32.70
Low
$17.17
Now
$20.44
High
$51.45

ACAD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 297.2% on average.

  1. Q3 FY24: reported $0.20 per share against an estimate of $0.1409
  2. Q4 FY24: reported -$0.02 per share against an estimate of $0.2204
  3. Q1 FY25: reported $0.11 per share against an estimate of $0.1136
  4. Q2 FY25: reported $0.16 per share against an estimate of $0.1398
  5. Q3 FY25: reported $0.42 per share against an estimate of $0.151
  6. Q4 FY25: reported $1.60 per share against an estimate of $0.1398
  7. Q1 FY26: reported $0.02 per share against an estimate of $0.0633
  8. Q2 FY26: reported $0.18 per share against an estimate of $0.0586

ACAD news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

  • Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

  • Press releaseBusiness Wire

    Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

  • Vandana Singh

    Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis

  • Avi Kapoor

    Crude Oil Rises Over 4%; Darden Earnings Miss Views

Similar companies

Companies in the same industry as ACADIA Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.